NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff MichalskiJeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer, Lisa A. Gurski

Research output: Contribution to journalReview articlepeer-review

168 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Original languageEnglish
Pages (from-to)1041-1053
Number of pages13
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Dive into the research topics of 'NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this